GLOBAL IS THE DESTINATION FOR TV'S TOP HITS THIS FALL, ANNOUNCING ITS 2025/26 LINEUP WITH SEVEN NEW ACQUISITIONS, ALONGSIDE TV'S #1 COMEDY, LATE NIGHT, REALITY SERIES*, AND RETURNING FAVOURITES
Ensemble Workplace Comedy DMV, Starring Harriet Dyer and Tim Meadows, Dick Wolf's New Procedural Drama CIA, Starring Tom Ellis, and Compelling New Drama Sheriff Country that Expands the World of Fire Country, Starring Morena Baccarin All Join Global's Fall Schedule
Global Also Adds Singing Competition Series The Road, From Taylor Sheridan, Blake Shelton and Keith Urban to Its Unscripted Slate
#1 Comedy Ghosts, #1 Reality Show Survivor, #1 Late Night Show Saturday Night Live Return this Fall to Global*
New Drama Y: Marshals (working title), Starring Luke Grimes, Culinary Competition America's Culinary Cup, Hosted, Created and Executive Produced by Padma Lakshmi, and True Crime Series Harlan Coben's Final Twist Come to Global Mid-Season
Stream Global Anytime with STACKTV and the Global TV App
For additional photography and assets, click here.
#CorusUpfront
TORONTO, June 2, 2025 /CNW/ - Today, Global revealed its 2025/26 broadcast season offering featuring seven star-studded new series as well as many of television's most-watched returning hits. Delivering an impressive 16.5 hours of simulcast programming and more scripted content than any other network in primetime this fall, Global's 2025/26 lineup spans every genre and is streaming on STACKTV and the Global TV App.
New this fall on Global is the single-camera workplace comedy DMV. Set at the U.S. Department of Motor Vehicles, DMV stars a brilliant and hilarious ensemble cast including Harriet Dyer, Tim Meadows, Tony Cavalero, Molly Kearney, Gigi Zumbado and Alex Tarranta. Then, joining the FBI-verse and from Emmy® Award-winning executive producer Dick Wolf, comes CIA starring Tom Ellis as a fast-talking, rule-breaking loose cannon CIA case officer. Next up is Sheriff Country starring Morena Baccarin as straight-shooting sheriff Mickey Fox, the stepsister of Cal Fire's division chief Sharon Leone (Diane Farr of Fire Country ) in an expansion of the Fire Country universe. Lastly, The Road is a new singing competition series from executive producers Taylor Sheridan, Blake Shelton and Keith Urban and follows GRAMMY® Award winner Urban on his journey to discover the next big artist with the help of 'tour manager,' GRAMMY® Award-winning country artist Gretchen Wilson. Full series descriptions of Global's new series for the fall are available here.
Global's fall lineup also features television's #1 hits including #1 comedy Ghosts, #1 late night show Saturday Night Live, fresh off celebrating its 50th anniversary, and #1 reality show Survivor*, back for its 49th season this fall and what promises to be a legendary 50th season in the spring. Other top 20-ranked shows returning to Global this fall include 9-1-1, FBI, Matlock, NCIS, NCIS: Origins and Elsbeth *. Also, Canadian-made Murder in a Small Town returns for a second season with Oscar® winner Marcia Gay Harden joining the cast and popular Canadian original true crime series Crime Beat is back for a seventh season.
Global's 2025/26 offering wouldn't be complete without Global News, which is home to Canada's #1 national newscast, Global National**, hosted by Canadian Screen Award winner Dawna Friesen, and The West Block, Canada's #1 Political Show in total audience*** airing Sunday mornings. In addition, The Morning Show, hosted by Carolyn Mackenzie and Jeff McArthur, continues to be Canada's #1 Canadian News/Lifestyle morning show and saw a year-over-year audience growth of 17% reaching 1.2 million Canadians weekly****, delivering audiences almost two times higher than Your Morning, and over two times higher than Breakfast Television*****.
The fresh content continues with more exciting new series joining the schedule mid-season starting with America's Culinary Cup, a new cooking competition series featuring the most decorated chefs in America and hosted and executive produced by Emmy® Award-nominated food expert Padma Lakshmi. Then, Y: Marshals (working title) is a new drama joining Taylor Sheridan's Yellowstone family of shows and stars Luke Grimes as Kayce Dutton. And finally, unscripted series, Harlan Coben's Final Twist, which features best-selling author Coben, with over 90 million books sold globally and multiple scripted series, as he steps into the true-crime television genre for the first time. Full series descriptions of Global's new mid-season series are available here. Also, bolstering Global's schedule mid-season is the return of hit series including Global Original Family Law, Watson and Hollywood Squares.
'This spring, Global was the only conventional network to experience year-over-year audience growth seeing a 7% increase in core primetime viewing******, delivering 12 of the top 20 programs – more than any other network*,' said Jennifer Abrams, Senior Vice President, Programming and Multiplatform, Corus Entertainment. 'With Global's new acquisitions for the upcoming broadcast season featuring the most-coveted series coming out of this year's L.A. screenings, paired with some of the most-watched returning series, Global is well-positioned to be the leader in bringing Canadian viewers what they want to see on their screens, entertaining audiences all year long.'
GLOBAL'S FALL 2025 SCHEDULE-AT-A-GLANCE
All times are ET and subject to change. New programs bolded.
A full list of premiere dates and times from Global's fall lineup will be announced in the coming months. For the latest updates, visit www.corusent.com.
Global's lineup of hit series are available to stream anytime on STACKTV, the Global TV App and GlobalTV.com.
Global is a Corus Entertainment Network and is available through all major TV distributors, including: Bell, Cogeco, Eastlink, Rogers, SaskTel, Shaw, Shaw Direct, Telus, Videotron and STACKTV, streaming available on Amazon Prime Video Channels, Bell Fibe TV app, FuboTV, Rogers Ignite TV and Ignite SmartStream. The Global TV App is available on iOS, Android, Chromecast, Android TV, Apple TV, LG Smart TVs, Amazon Fire TV, Samsung Smart TVs, Roku streaming players, Roku TV™ models, and at watch.globaltv.com.
Sources:
*Numeris PPM Data,. Total Canada, SP'25 STD (Jan 6 – Apr 20/25) – confirmed to Apr 13/25, A25-54, AMA(000), CDN CONV COM ENG, all stations based on 'Total' except for CTV Com, 3+ airings, excludes NFL Playoffs
**Numeris PPM Data,. Total Canada, SP'25 STD (Jan 6 – Apr 20/25) – confirmed to Apr 13/25, A18+, AMA(000), CDN CONV COM ENG, 3+ airings, Mon-Fri airings only, National Network
***Source: Numeris PPM Data, Total Canada, SP'25 STD (Aug 26/24 - Apr 20/25) - confirmed data, Ind. 2+ AMA(000), Total of all individual conventional + specialty airings , 3+ airings
****Source: Numeris PPM Data, Total Canada, Broadcast Year-to-date (Aug 26/24 – Apr 13/25) – confirmed,Ind2+, AvWkRch(000)
*****Numeris PPM Data, Broadcast Year-to-date (Aug 26/24 – Apr 13/25) – confirmed to Apr 6/25, Total Canada, Mo-Fri 6a-12p, Based on Canadian news/lifestyle morning show genre, CDN CONV COM ENG, CTV based on 'Com', all other networks based on 'Total', 3+ airings, A18+ AMA(000), growth based on same weeks YoY
******Numeris PPM Data,. Total Canada, SP'25 STD (Jan 6 – Apr 20/25) vs. SP'24 STD (Jan 8 – Apr 21/24) – confirmed to Apr 13/25, A25-54, AMA(000), Full day (Mo-Su 2a-2a)/Primetime (Mo-Su 8-11p)/Off-prime (Mo-Su 2a-8p, 11p-2a), local time
SOCIAL MEDIA LINKS:
Facebook:
https://www.facebook.com/GlobalTV
Instagram:
@globaltv
TikTok:
@globaltv
LinkedIn:
https://www.linkedin.com/company/corus-entertainment
About Corus Entertainment Inc.
Corus Entertainment Inc. (TSX: CJR.B) is a leading media and content company that develops, delivers and distributes high quality brands and content across platforms for audiences around the world. Engaging audiences since 1999, the company's portfolio of multimedia offerings encompass 30 specialty television services, 36 radio stations, 15 conventional television stations, digital and streaming platforms, and social digital agency and media services. Corus' roster of premium brands includes Global Television, W Network, Flavour Network, Home Network, The HISTORY® Channel, Showcase, Slice, Adult Swim, National Geographic and Global News, along with streaming platforms STACKTV, TELETOON+, the Global TV App and Curiouscast. For more information visit www.corusent.com.
SOURCE Corus Entertainment Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
22 minutes ago
- Gizmodo
HP 14″ Laptop With Office For Life Is Cheaper Than AirPods, Amazon Is Clearing Stock at 74% Off
Purchasing a proper Windows laptop from respected brands like HP, Dell, or Lenovo generally costs you over $1,000. But right now, Amazon has a deal that is nearly too good to ignore: there's an HP 14 laptop (385GB storage, 16GB RAM) available for an all-time low price of just $359 which is a huge 72% discount from its normal $1,299 price. It also includes a bundle of extras that make it even more valuable: a one-time Microsoft Office license for life, a DVD drive for free, and a Micro-SD card with 256GB of storage space for extra room. With such a low price and so many premium features included, this HP laptop is a steal. See at Amazon Perfect Laptop for Day to Day Tasks At the heart of this HP 14 lLaptop is an Intel N150 processor with 4 cores and 4 thread, capable of reaching speeds up to 3.2 GHz. This configuration ensures good and smooth multitasking whether you're juggling multiple browser tabs, working on documents or streaming content. The laptop comes with 16GB of DDR4 RAM and 128GB of ultra-fast UFS storage, offering snappy performance and quick access to files and applications. For those who need even more space, the included 256GB Micro-SD card provides ample room for storing more documents. The 14-inch BrightView HD anti-glare display features micro-edge bezels and it is ideal for entertainment-oriented gameplay or uncluttered dual-monitor set-ups. The screen offers vibrant colors and sharp text so that your content can come life while watching movies, photo editing, or creating presentations. The thin and light design, weighing just 3.24 pounds and measuring 0.71 inches thick makes it a breeze to take back and forth from class to class or on a business adventure. Thanks to battery life of up to 11 hours of video play and the benefit of fast-charge technology, you can maintain productivity and entertainment all day long. It includes the newest Wi-Fi 6 technology for fast, secure internet connection and an included DVD drive (a privilege on most modern laptops) so that you can access to old media or software installation from disks. A DVD drive is especially convenient for students and professionals who continue to utilize physical media. The laptop can also use external screens, making it a great choice for productivity-based setups in the home or office. It comes pre-loaded with Windows 11 Pro, offering advanced security functionalities and an easy-to-use interface designed for productivity. The one-time Microsoft Office lifetime license is also a big bonus, giving you unlimited access to handy programs like Word, Excel, and PowerPoint with no additional subscription fee. The addition of Copilot AI also enhances productivity, providing intelligent assistance in writing, editing, and data analysis. This limited time deal is awesome, make sure you don't miss it. See at Amazon
Yahoo
35 minutes ago
- Yahoo
Patents and economies of scale support Pfizer's wide moat
Pfizer's innovative business should grow faster after it divests its off-patent division Upjohn in 2020 to create Viatris and Mylan. With fewer older medications and fewer patent losses, Pfizer is well-positioned for consistent growth, excluding the erratic sales of Covid-19-related products. The company is less vulnerable to any one patent loss thanks to its wide range of medications. Because of its more complex manufacturing process and more affordable prices, Pfizer's stronger position in the vaccine marketwhich includes the pneumococcal vaccine Prevnarmakes it more resilient to generic competition. Warning! GuruFocus has detected 6 Warning Signs with PFE. With a 30% to 80% reduction, Trump's executive order would establish a "most favored nation" policy in which the US would pay the same amount for prescription medications as the nation with the lowest price. It is anticipated that this policy, which was previously blocked by courts, will reduce the US's annual drug spending of over $400 billion, saving taxpayers over a seven-year period. Given that drug prices in the United States are high when compared to other countries, Pfizer's U.S. revenue could be drastically impacted by the 30% to 80% price cut, especially for high-margin medications. International reference pricing policies have long been opposed by the pharmaceutical industry, which claims they could hinder innovation and limit access to new companies anticipate that the order will target Medicare and may have an impact on medications not covered by Biden's Inflation Reduction Act. President Trump has said that significant tariffs on pharmaceutical products will probably be announced soon. He has also put a 90-day hold on broader tariffs for the majority of his trading partners to give them time to negotiate. Despite being mostly exempt from tariffs, the biopharma industry is preparing for a possible pharma-specific announcement that might affect global manufacturing strategies. Products made in Europe and imported into the US may be subject to the rumored 25% tariff, necessitating the construction of new facilities that will take years to complete. Due to home country manufacturing, tax benefits, lower production costs, and exposure to currency fluctuations, businesses based in the US and Europe are heavily exposed to European manufacturing. Because drug spending is not cyclical, the direct effect of tariffs on earnings is probably going to be minimal, and the indirect effect of a possible recession should also be minimal. With the exception of small-scale US capacity expansions, biopharma is unlikely to completely reevaluate its manufacturing footprint if pharmaceutical tariffs are implemented but are lifted after 2026 as a result of political pressure from the midterm elections. Leadership in Vaccines Pfizer stands out with its dominant position in vaccines, most notably its highly successful COVID-19 vaccine developed in partnership with BioNTech. This vaccine not only generated significant revenue but also established Pfizer as a leader in mRNA technology, a platform with potential applications in oncology, rare diseases, and beyond. Johnson & Johnson (J&J): J&J also developed a COVID-19 vaccine, but it was less widely adopted due to lower efficacy rates and safety concerns, giving Pfizer a clear advantage in this high-impact area. GlaxoSmithKline (GSK): GSK has a strong vaccine portfolio (e.g., shingles and meningitis vaccines) but did not independently develop a COVID-19 vaccine, relying on partnerships like Sanofi, which delayed its entry and diminished its competitive stance. Bristol Myers Squibb (BMS): BMS has no significant presence in vaccines, focusing instead on oncology and immunology, making Pfizer's vaccine leadership a unique strength. R&D Capabilities and Pipeline Focus Pfizer's R&D efforts are concentrated on high-growth therapeutic areas such as oncology, vaccines, and rare diseases. Its ability to leverage mRNA technology and rapidly develop innovative therapies underscores its R&D prowess. J&J: J&J's R&D spans pharmaceuticals, medical devices, and consumer health. While this diversification provides stability, it may dilute J&J's focus on cutting-edge pharmaceutical innovation compared to Pfizer's targeted approach. GSK: GSK excels in respiratory diseases and HIV research, but its pipeline is less broad and lacks the same level of innovation in emerging technologies like mRNA that Pfizer is advancing. BMS: BMS has a strong oncology pipeline, particularly in immuno-oncology, but its narrower focus limits its competitiveness in other high-growth areas where Pfizer thrives, such as vaccines and rare diseases. Global Reach and Market Presence Pfizer operates in over 150 countries, giving it a vast global footprint that enhances its ability to distribute products and capture market share across both developed and emerging markets. J&J: J&J also has a global presence, but its focus is split across pharmaceuticals, medical devices, and consumer health, potentially reducing its pharmaceutical market penetration compared to Pfizer. GSK: GSK is strong in Europe and emerging markets but less dominant in the U.S., the world's largest pharmaceutical market, where Pfizer has a significant advantage. BMS: BMS focuses heavily on the U.S. and Europe, with less presence in emerging markets, limiting its global scale compared to Pfizer. Brand Reputation and Trust The success of Pfizer's COVID-19 vaccine has significantly boosted its brand recognition and trust among consumers, healthcare providers, and governments, reinforcing its market position. J&J: J&J enjoys a strong reputation in consumer health, but its pharmaceutical division lacks the same level of visibility and trust as Pfizer's, particularly after COVID-19 vaccine challenges. GSK: GSK is well-regarded in respiratory and HIV treatments but does not have the broad public recognition that Pfizer has achieved. BMS: BMS is respected in oncology but lacks the widespread brand prominence that Pfizer has cultivated. Innovation in Emerging Technologies Pfizer's investment in mRNA technology positions it as a pioneer in pharmaceutical innovation, with potential applications in vaccines, cancer treatments, and more, giving it a forward-looking edge. J&J: J&J innovates in medical devices and consumer health but trails Pfizer in adopting next-generation pharmaceutical technologies like mRNA. GSK: GSK focuses on innovation in respiratory and HIV treatments but has not made significant advances in mRNA or other emerging platforms. BMS: BMS drives innovation in immuno-oncology but lacks Pfizer's breadth and leadership in cutting-edge technologies. Pfizer's competitive edge over Johnson & Johnson, GlaxoSmithKline, and Bristol Myers Squibb lies in its unmatched leadership in vaccines, particularly through mRNA technology, combined with a robust R&D pipeline, extensive global reach, substantial financial resources, strong brand reputation, and a focus on innovation. While J&J benefits from diversification, GSK from efficiency, and BMS from oncology expertise, none rival Pfizer's comprehensive strengths across these critical areas, ensuring its dominance in the pharmaceutical landscape. Pfizer's broad moat is supported by patents, economies of scale, and a strong distribution network. Strong pricing power derived from Pfizer's patent-protected medications allows the company to produce returns on investment that exceed its cost of capital. The company can develop the next generation of drugs before generic competition appears thanks to the patents. Furthermore, even though Pfizer has a wide range of products, there is some product concentration, as Prevnar accounts for slightly more than 10% of total sales (not including sales of the COVID-19 vaccine).However, because of the vaccine's complicated manufacturing process and comparatively low cost, we don't anticipate typical generic competition. Ibrance and Eliquis each account for nearly 10% of sales. On the other hand, we anticipate that new products will eventually lessen the competition from generic versions of important medications. In order to lessen the pressure on margins from lost sales of high-margin drugs, Pfizer's operating structure permits cost-cutting after patent losses. All things considered, Pfizer's well-established product line generates the massive cash flows required to cover the typical $800 million in development expenses for each new medication. For smaller pharmaceutical companies without Pfizer's resources, the company's robust distribution network positions it as a solid partner. On April 15, President Donald Trump issued an executive order outlining possible policy changes intended to reduce the cost of pharmaceuticals in the United States. The biopharma industry is looking forward to these changes because they have the potential to either help or hurt innovation. In the worst situation, international price benchmarks have the potential to drastically cut US drug prices and lessen financial incentives for international drug development. On the plus side, eliminating the "pill penalty" that only grants small molecule medications nine years of Medicare negotiation protection may promote innovation across all treatment modalities. Trump's executive order may have a positive or negative impact on the industry, but it has no effect on valuations or uncertainty ratings. The protection period is not specified in Trump's request that US Department of Health and Human Services Secretary Robert F. Kennedy Jr. collaborate with Congress to address the pill penalty, which is contingent upon Congressional action. Since innovation and a favorable mergers and acquisitions climate support long-term pricing power and offset possible short-term tariff pressure, rising tax rates, and approval delays, the biopharma industry seems undervalued. Due to liver damage in a clinical trial, Pfizer has announced the discontinuation of danuglipron, an oral small molecule GLP-1 agonist. In the anticipated $200 billion global GLP-1 market by 2031, the company sought to provide a potential second-to-market oral small molecule GLP-1 agonist, behind Lilly's orforglipron. Clinical trial failures and declining demand for Pfizer's COVID vaccine and antiviral medication have hurt the company's growth. Because of its diverse pipeline and portfolio, Pfizer is expected to have a wide-moat case, protecting it from the effects of individual program failures, especially those involving high-risk programs like danuglipron. Other medication candidates might benefit from Pfizer's objective of turning danuglipron into a once-daily business could use its $15 billion acquisition budget to fund the development of more sophisticated medication candidates. Efforts in Genetic Engineering: A solid growth driver for Pfizer is the strong pipeline of innovative treatment options, especially in oncology and immunology, which take the leap with cutting-edge scientific technology. To be more specific, Pfizer's resource allocation to immuno-oncology is evident, developing of checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors) and chimeric antigen receptor T-cell (CAR-T) therapies. For instance, this method of treatment mitigates the immune system's ability to detect and destroy the specified cancer cells by varying the immune system response or, in some cases, by using specially modified T-cells that can identify the particular antigens on tumors that are solely expressed in those particular tumors, which are in question. This is the area of advancement where Pfizer has outdone the rest as they are perfecting monoclonal antibody formatsdesigning them in a way that they will bind more tightly and specifically to targets using protein engineeringand they are also testing out bispecific antibodies that trigger switches at two targets, therefore enhancing healing by more than one method. The pipeline is further supported by vast R&D investment in gene therapy and precision medicine, which utilize adeno-associated virus (AAV) vector platforms for gene delivery and next-generation sequencing for actionable mutation identification respectively. These endeavors are aimed at enhancing the overall patient health and market potential of the drugs by changing the treatment convention from testing a wide spectrum to one that is genotype-driven. Clinical trials are usually designed in a way to be fast-tracked so that they can move quickly to the next stage of development. By focusing on such advanced technologies, Pfizer is embarking on capturing a large section of the market with high-growth therapeutic branches, thus gaining revenue through innovation guided by complex disease biology. Revenue Growth: The launching of these high-value treatments is expected to increase revenue as well as drive down costs for Pfizer. Most of the drugs that are released in the onco-immunology field possess a technical edge and therapeutic effectiveness, therefore, these new treatements often demand high price. These drugs are capable of pumping up profits significantly once they clear regulatory hurdles and find their way onto the market. take the example of just-above successful immuno-oncology drug sales, which always have brisk selling and marvelous sales. In addition, Pfizer can speed-up the whole clinical process with something like adaptive trial designs, this process will be quicker and thus benefits are obtained faster from the new products. Impact on profitability The weight on profitability depends on the ratio of costs and returns. What is actually known is that lamas like the checkpoint inhibitors and CAR-T treatments that are so good require a lot of investment in R&D. But there is an inherent advantage for these drugs thanks to their patent protection that comes with market exclusivity, which in turn, allows Pfizer to keep its pricing strategy stick and generate very high profits. Success in the selling of the product along the lines of this new dimension along with the efficiency of producing more could prove to be the road to better profitability. However, there are barriers such as competition from other drug companies plus the worry of the price cuts from payers that can erode this success. So if Pfizer is able to eliminate the competition and stays ahead in the game by reducing costs as well, these high markups brought about by the introduction of such innovative drugs should positively affect the total profitability of the company. Generic competition, possible changes to government drug pricing policies, the more stringent FDA, and more powerful managed-care and pharmacy benefit managers present Pfizer with difficulties in drug development. In some disease areas, developing new drugs is getting harder, and pharmacy benefit managers and managed-care organizations have grown to be strong players with the ability to bargain for cheaper drug costs. Nearly one-fourth of the company's total sales are generated by its medications, Eliquis, Ibrance, and Xtandi, and they are heavily exposed to the Medicare channel. Given that Pfizer's product portfolio is less vulnerable to potential litigation, the company's base-case annual legal costs, assuming a 50% probability of future costs associated with product governance ESG risks, come close to 1% of non-GAAP net income. Pfizer's valuation multiples highlights their strong financial position and potential undervaluation. Their P/E Non-GAAP ratios7.61 (FY1), 7.42 (FY2), and 7.44 (FY3)are lower than JNJ's 14.00 (FY1) and SNY's 10.80 (FY1), suggesting investors may undervalue our earnings potential. The PEG Non-GAAP (FWD) of 1.49 is competitive, higher than SNY's 0.76 but below JNJ's 1.70, reflecting moderate growth prospects. Pfizer's EV/Sales (TTM) of 2.81 is more conservative than JNJ's 4.21, while the EV/EBITDA (FWD) of 7.13 compares favorably to JNJ's 11.45, indicating operational efficiency. The Price to Book (TTM) of 1.44 is significantly lower than JNJ's 5.23, and our Price to Cash Flow (TTM) of 9.29 beats JNJ's 15.67, underscoring robust cash flow generation. These metrics position Pfizer as a value opportunity among peers After the Seagen acquisition, Pfizer released its 2024 guidance, which included a $8 billion COVID-19 product guidance$5 billion less than anticipated. The business admitted that, excluding sales of COVID-19 products, it would not meet the prior growth-rate projection of 6% from 2020 to 2025. Pfizer reaffirmed its support for the dividend, which is regarded as safe and likely to boost stock valuation, despite the deteriorating outlook. Over the next ten years, the company anticipates steady sales as new products counteract older medications that are losing their patent protection. From the middle of 2023 to the end of 2024, Pfizer is anticipated to reduce operating expenses by $4 billion, which will aid the company in adjusting to the waning pandemic and declining sales of COVID-19 products. Growth could be accelerated through acquisitions, and future margin pressure could be reduced through restructuring initiatives. It is estimated that Pfizer's weighted average cost of capital is 7% and its cost of equity is 7.5%. Activist investor Jeffrey Smith's recent stake worth $407 million could presage the much needed turnarounds at Pfizer. Investors and shareholders can reasonably expect further cost-cuts and an efficient use of capital, leading to higher margins and free cashflow. This case could follow the path of Walt Disney, albeit with less drama, where Jeff Ubben of ValueAct had a pivotal role in Disney's turnaround campaign. The large-cap biopharma company Pfizer's debt size, business cyclicality, and debt maturity outlook all contribute to its sound balance sheet and low risk levels. To support opportunistic acquisitions and handle product litigation issues with little market concern, the company should have a strong enough balance sheet. Pfizer spends slightly less on R&D than the industry average, with a mid- to high-teens percentage of sales. Patent losses are offset by the company's robust pipeline of next-generation medications. The company's investment in cutting-edge new medications, mostly aimed at immunology and oncology, improves its standing and increases returns on capital. For biopharma companies in the sector, this balance sheet strength is essential. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
35 minutes ago
- Yahoo
Rocket Lab Stock Is Soaring Again: Should You Buy It Under $30?
Rocket Lab is gaining a reputation for reliability in the rocket launch and space systems market. The company is building on its capabilities and improving its relationships as a defense contractor. While this young sector shows a lot of great promise, the stock looks overvalued today. 10 stocks we like better than Rocket Lab › Space is the final frontier, and it is now turning into a burgeoning economy. Researchers estimate that the space economy is worth over $500 billion with heavy spending from governments around the world along with private-company partners, and that figure is expected to grow to around $1.8 trillion a year by 2035. This is a huge opportunity for start-ups, perhaps rivaled only by artificial intelligence (AI) over the next decade when it comes to both growth rates and size. One company that dominates (and actually built) the entire space market is SpaceX. It's privately held, but luckily, investors have other space economy stocks that are turning into promising businesses. Enter Rocket Lab (NASDAQ: RKLB), the space flight company increasingly competing with SpaceX and developing promising capabilities to grow its presence in this large market. The stock has begun to soar again and is trading at around $26 as of this writing. Should you buy while shares are still under $30? Rocket Lab began its journey in the space economy with its small Electron rocket. It has now begun to expand and vertically integrate various space economy segments. It just acquired a company called Geost for $275 million. Geost develops optical and infrared capabilities for satellites with a focus on selling to the U.S. government's national security satellites. Rocket Lab is used by the government to launch its payloads into space. Now, it will be helping to build and operate these payloads for customers. It keeps vertically integrating its launch and space systems, which gives it a competitive advantage over other companies that only offer one or the other (SpaceX is the only other vertically integrated player). Rocket Lab offers solar energy, radio systems, and software for companies sending missions operating in space. This is why its backlog was over $1 billion as of the end of last quarter. Electron launch missions will continue throughout 2025, hopefully building on the company's strong safety and reliability record. The next step for the company will be testing and launching its larger Neutron rocket for customers. Testing is underway for this rocket right now with a planned mission for a confidential customer sometime in 2026. Larger rockets mean larger payloads, which means more revenue per launch. It also will give the company more of an opportunity to sell its space systems on these launches. The Neutron is the key for Rocket Lab to take the next step in its capabilities as a space flight company and to grow its backlog and revenue. Defense contracts have been a huge part of Rocket Lab's business. It currently helps with Air Force missions and a hypersonic testing program called HASTE. It was recently added to the National Security Space Launch (NSSL) program for its Neutron rocket, another reason why this new rocket is so important for the company's future. A growing relationship with the U.S. government could not have come at a better time for Rocket Lab. The government is set on spending a ton of money on space solutions as the next frontier in national defense. For example, the proposed Golden Dome missile defense project for the U.S. would cost an estimated $175 billion over three years to build. The company would be a prime candidate to win subcontracts for this ambitious project. As the Neutron comes on line and Rocket Lab builds up its capabilities and reputation in the space economy, we should see its backlog climb higher. This is a key indicator for investors to watch. The current backlog will have around half of its revenue recognized over the next 12 months, and half in later periods. In order to grow revenue over the long term, the company will need to grow its backlog and win more contracts from government and commercial customers. There is a lot of potential with Rocket Lab's business, but it might all be priced into the stock (and more) right now. It has a market cap of $12.3 billion. Revenue was only $466 million over the last 12 months. The company has never generated a profit and continues to lose money. If the company is successful with its ambitions to build a vertically integrated space company, it will eventually generate billions of dollars in revenue -- perhaps tens of billions 15 to 20 years from now. However, that is a long way off, and the stock looks fully priced versus what the company can accomplish in the next few years. For this reason, the stock looks like one to avoid even with the price under $30. The business may be promising, but the market is getting ahead of itself with Rocket Lab at the moment. This is a high-risk stock to keep out of your portfolio right now. Before you buy stock in Rocket Lab, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Rocket Lab wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Rocket Lab USA. The Motley Fool has a disclosure policy. Rocket Lab Stock Is Soaring Again: Should You Buy It Under $30? was originally published by The Motley Fool
